Hero - CBN vs CBD
Home/Compare/CBN vs CBD

CBN vs CBD: What the First Sleep Trial Actually Found

CBD is a compound the plant makes on purpose. CBN is what THC turns into when cannabis gets old. That origin difference is the most important thing about this comparison. CBN is widely sold as a sleep aid, but the first proper sleep trial, published in 2026, missed its primary endpoint, and it used 300 mg where consumer products contain 1 to 5 mg.

Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic
Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic

At a glance

Property
CBN
CBD
How it forms
Oxidation of THC on exposure to air, heat and light
Decarboxylation of CBDA, a deliberate plant product
CB1 receptor
Weak partial agonist. pEC50 5.4, maximum effect 29 percent
No meaningful activation, negative allosteric modulator
Active metabolite
11-OH-CBN, a CB1 agonist roughly as potent as THC
7-OH-CBD, less potent than the parent
Intoxicating
Weakly, at very high doses only
No
Most potent target
TRPA1, EC50 0.18 μM
ENT1 adenosine transporter, Ki under 250 nM
Human sleep trials
One. Primary endpoint failed
None adequate
Human pharmacokinetics
None published
Partially characterized
Approved medicine
None
Epidiolex
What its presence indicates
Product age or THC degradation
Deliberate formulation

CBN is a degradation product, not a plant product

This is the fact the category tends to skip past.

Cannabis does not have an enzyme that makes CBN. There is no CBNA synthase. CBN forms when THC sits in contact with oxygen, warmth and light, and the terpene ring aromatizes. Old, badly stored cannabis has high CBN because its THC has broken down. Heating cannabis produces CBN too. In one 2022 analysis, 17.2 percent of delta-9 THC degraded in a gas chromatograph inlet, generating CBN.

Practically, this means CBN content in a hemp product is a marker of what has happened to the material rather than a marker of intentional cultivation. Concentrated CBN products are made by deliberately degrading THC or by synthesis.

CBD is the opposite. The plant builds CBDA through a dedicated enzyme, and CBD is what CBDA becomes when heated.

The pharmacology

Inner - CBN vs CBD

CBN is a weak, low-efficacy partial agonist at CB1. A 2025 study in Neuropsychopharmacology measured pEC50 5.4 with a maximum effect of 29 percent, against THC’s pEC50 6.4 and 72 percent. Older work using a different assay reported an EC50 around 0.12 micromolar, roughly thirty times more potent. Both are legitimate measurements from different systems, which is a useful reminder that single numbers quoted without their assay context are not very meaningful.

The more interesting finding in that 2025 paper concerns CBN’s metabolite. 11-hydroxy-CBN reaches brain concentrations equivalent to CBN itself, and it is a CB1 partial agonist with potency and efficacy comparable to THC: pEC50 6.0, maximum effect 75 percent. So if CBN does anything centrally, its metabolite is probably doing much of the work.

That also creates a theoretical route to intoxication at high oral doses, which is why the honest answer to “is CBN psychoactive” is “weakly, at doses far above what anyone sells.”

CBN’s most potent measured action is at TRPA1, a sensory ion channel, with an EC50 of 0.18 micromolar. It is a TRPM8 antagonist at 0.21 micromolar. At CB2 it is negligible.

CBD, as covered elsewhere on this site, works mainly outside the cannabinoid receptor system altogether.

The sleep question, answered properly

CBN
A 2021 review in Cannabis and Cannabinoid Research searched the literature systematically and found the research on CBN dated and limited, mostly from the 1970s and 1980s, with rare assessment of sedation and no published clinical trials using validated sleep questionnaires or polysomnography.
Published in the Journal of Sleep Research, it was randomized, double-blind, placebo-controlled, three-arm and crossover, in 20 adults with physician-diagnosed insomnia disorder, using overnight polysomnography.
The primary endpoint failed. Wake after sleep onset, the time spent awake during the night, was not significantly changed: 6.3 minutes less on 300 mg with a confidence interval running from minus 18.2 to plus 5.5 minutes, p equals 0.29.
Some secondary measures at the 300 mg dose did move: more stage 2 non-REM sleep, better subjective sleep quality, faster sleep onset, fewer EEG arousals.
Consumer CBN gummies typically contain 1 to 5 mg. That is sixty to three hundred times less.

CBN is marketed almost exclusively for sleep. It is worth understanding where that idea came from, because it did not come from research.

The reasoning ran like this. Aged cannabis has a reputation for being sedating. Aged cannabis has high CBN. Therefore CBN is sedating. That is a confound, not a finding. Aged cannabis differs from fresh cannabis in many ways, including substantial terpene loss and reduced THC.

A secondary source of confusion is 1970s literature describing nabilone as a “potent antiemetic cannabinol.” Nabilone is a synthetic THC analogue. It is not CBN.

Rat polysomnography does show CBN increasing total sleep time, with the effect apparently driven substantially by the 11-OH-CBN metabolite. That is genuine science. It is also a rat.

There is no evidence at consumer doses, and it is not obvious why anyone should expect an effect there.

What people get wrong

01CBN is the sleep cannabinoid.
Folklore, not data. The first proper trial missed its primary endpoint.
02CBN is as effective as a sleeping pill.
No trial supports this. The rat study found the non-REM effect comparable to zolpidem, but rats are not people and the human trial did not replicate that.
03CBN is aged THC so it must be relaxing.
The premise is right and the conclusion does not follow.
045 mg of CBN will help me sleep.
There is no evidence at that dose. If a product works for you, that is worth something to you personally, but it is not something a manufacturer should claim. One further point worth knowing before buying a CBN and melatonin combination product: preclinical work published in 2025 suggests a CBN and melatonin interaction. It has not been characterized in people.

Choosing between them

If your interest is sleep specifically, neither compound has adequate human evidence at consumer doses. CBD has no adequate sleep trial base at all, and drowsiness appears in the epilepsy trials as a side effect rather than a benefit. CBN has one trial that missed its primary endpoint at a dose sixty times higher than what is sold.

We would rather tell you that than sell you a story. If you want to try CBN, look at the actual milligram content and understand that you are well below any studied dose.

Still weighing up the options? See CBN vs CBC, CBG vs CBN or CBD vs melatonin. Endoca products related to this comparison: CBN products and CBD for sleep products.

How Endoca tests for this

CBN appears on every Endoca certificate of analysis, and we report it whether or not it flatters the product, because in a full-spectrum extract CBN content tells you something real about how the material was handled. Low CBN in a CBD product is a sign of good storage and fresh extraction. That is a quality signal, and it is the opposite of the signal a CBN-marketed product is trying to send.

Frequently asked questions

The first controlled trial in people with insomnia did not find a significant effect on time spent awake at night, at either 30 mg or 300 mg. Some secondary measures improved at 300 mg.

Weakly, and only at doses far above what is sold. Its metabolite is a THC-strength CB1 agonist, which is the mechanism of concern.

Usually a fraction of a percent, and it rises as the product ages.

It occurs naturally as a breakdown product. Concentrated CBN in products is typically produced deliberately from THC.

Neither has adequate evidence at consumer doses. We would rather say so.

Many products combine them, and both are found together in full-spectrum hemp extracts. There is no human trial showing the combination works better for sleep than either one alone.

They are not comparable on a single scale. CBN acts weakly on the CB1 receptor, while CBD barely binds to it at all and works through other routes. Stronger depends on which effect you measure.

References

01

Lavender I et al. The effects of cannabinol on sleep in insomnia disorder. J Sleep Res 2026;35:e70284.

02

Arnold JC et al. Cannabinol and its metabolite 11-OH-CBN in sleep. Neuropsychopharmacology 2025;50:586-595.

03

Corroon J. Cannabinol and Sleep: Separating Fact from Fiction. Cannabis Cannabinoid Res 2021;6:366-371.

04

De Petrocellis L et al. Effects of cannabinoids on TRP channels. Br J Pharmacol 2011;163:1479-1494.

05

Garcia-Valverde MT et al. Thermal degradation of cannabinoids. Front Chem 2022;10:1038729.

06

Husni AS et al. Evaluation of phytocannabinoids at CB1 and CB2. Med Chem Res 2014.

07

Congressional Research Service. Legal Sidebar LSB11381, updated 22 December 2025.

Last reviewed 1 September 2026.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.